YS Biopharma Raises Concerns About Validity of Extraordinary General Meeting
YS Biopharma Co., Ltd. (NASDAQ: YS), a prominent biopharmaceutical company, is facing questions about the validity of an extraordinary general meeting (EGM) called by a group of shareholders. The company has asserted that the notice for the EGM, which aims to remove six out of seven directors, does not comply with the necessary procedural requirements.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
